Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …
Carrie Carda, MD, on peptide therapy for PMOS, endometriosis, and fertility Contemporary OB/GYN
Banana Blossom Peptides Show Endometriosis Research Potential EMJ
Banana Blossom Peptides Show Endometriosis Research Potential emjreviews.com
Endometriosis is a chronic inflammatory condition that affects an estimated 1 in 10 women but is often mis- and underdiagnosed due to its non-specific symptoms and the lack of a …
The human microbiome, a dynamic endocrine organ, exerts profound systemic influence through the production of bioactive metabolites. While the microbiome-gut-brain axis is well-established, the direct conduit between the gut microbiota …
Background: Endometriosis and lipedema are chronic female-predominant disorders characterized by persistent pain that is frequently disproportionate to anatomical lesion burden. Although traditionally interpreted within distinct lesion-centered frameworks, both conditions exhibit …
Endometriosis, a chronic inflammatory disease affecting 10-15% of women of reproductive age, remains a leading cause of female subfertility. While current management strategies focus on surgical excision and hormonal suppression, …
Endometriosis is increasingly recognized as a chronic systemic disorder extending beyond the classical estrogen-dependent paradigm, integrating metabolic, immune, fibrotic, and nociceptive pathways that sustain lesion persistence and refractory pelvic pain. …
Calcitonin gene-related peptide (CGRP), a neuropeptide, has been implicated in autoimmune diseases, endometriosis, tumors, and primary headaches, including migraine. The development of a novel, fast-acting CGRP receptor antagonist administered via …